BTIG analyst Justin Zelin reiterated a Neutral rating on Tscan Therapeutics Inc (NASDAQ: TCRX).The analyst commented: "We are reiterating our ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE